Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$10.54 - $18.14 $913,638 - $1.57 Million
-86,683 Reduced 43.34%
113,317 $1.81 Million
Q1 2024

May 13, 2024

BUY
$6.63 - $17.3 $1.33 Million - $3.46 Million
200,000 New
200,000 $2.94 Million

Others Institutions Holding PEPG

About PepGen Inc.


  • Ticker PEPG
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 23,631,900
  • Market Cap $85.8M
  • Description
  • PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is a...
More about PEPG
Track This Portfolio

Track Artal Group S.A. Portfolio

Follow Artal Group S.A. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

News

Stay updated on Artal Group S.A. with notifications on news.